Full Press Release Details
eylea hd aflibercept injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vei.
REGN
eylea hd aflibercept injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vei
Key Takeaway: eylea hd aflibercept injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vei